Spectrum Of Activity
Complicated UTI (including pyelonephritis)Complicated intraabdominal infection in combination with MetronidazoleHAP/VAP1.5 g (Ceftolozane 1 g/Tazobactam 0.5 g) IV infused over 1h q8h x7d1.5 g IV q8h x4-14d + Metronidazole 500 mg IV q8h3 g (Ceftolozane 2 g/Tazobactam 1 g) IV infused over 1h q8h x8-14d
Safety and efficacy in pediatric patients have not been established
No dose adjustment
CrCl 30-50CrCl 15-29CrCl <15, HD- IAI, UTI: 750 mg IV q8h
HAP/VAP: 1.5 g IV q8h- IAI, UTI: 375 mg IV q8h
HAP/VAP: 750 mg IV q8h- IAI, UTI: 750 mg IV load, then 150 mg IV q8h (dose after HD on HD days)
HAP/VAP: 2.25 g IV load, then 450 mg IV q8h (dose after HD on HD days)
In patients with documented multi-drug resistant (MDR) Pseudomonas or CRE organisms
Complicated urinary tract infection
Hospital acquired pneumonia
Infectious disease of abdomen, Complicated disease, in combination with metronidazole
Improvement in signs and symptoms of infection are indicative of efficacy.
Monitor patients with changing renal function; CrCl at least daily.
Consider monitoring renal function on elderly patients.
Clostridium difficile colitis
Clostridium difficile diarrhea
Cholera vaccine - reduced immune response to the cholera vaccine
Probenecid - increased risk of elevated tazobactam serum concentrations
Antimicrobial Class: Cephalosporin, Penicillinase inhibitor
Pregnancy Category: B
Average serum half life: 1.9-4 hours (Ceftolozane), 0.7-3 hours (Tazobactam)
Urine penetration: Therapeutic
Lung penetration: Therapeutic
Increased risk of adverse effects in patients with moderate or severe renal impairment and those with ESRD on hemodialysis; monitoring recommended and dose adjustments required.
Decreased efficacy has been reported in patients with baseline creatinine clearance of 30-50 mL/min; monitoring recommended.
Infectious Diseases consult required for use (intensivists can order empirically in the ICU, if known MDR organism until ID can be consulted).
Should be reserved for patients with little or no other treatment alternatives.
Attribution: Antimicrobial information adapted from Sault Area Hospital